161 related articles for article (PubMed ID: 28917029)
1. Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma.
de Groot S; Redekop WK; Versteegh MM; Sleijfer S; Oosterwijk E; Kiemeney LALM; Uyl-de Groot CA
Qual Life Res; 2018 Jan; 27(1):115-124. PubMed ID: 28917029
[TBL] [Abstract][Full Text] [Related]
2. Health-Related Quality of Life and Health Utilities in Metastatic Castrate-Resistant Prostate Cancer: A Survey Capturing Experiences from a Diverse Sample of UK Patients.
Lloyd AJ; Kerr C; Penton J; Knerer G
Value Health; 2015 Dec; 18(8):1152-7. PubMed ID: 26686802
[TBL] [Abstract][Full Text] [Related]
3. Mapping EORTC-QLQ-C30 to EQ-5D-3L in patients with colorectal cancer.
Marriott ER; van Hazel G; Gibbs P; Hatswell AJ
J Med Econ; 2017 Feb; 20(2):193-199. PubMed ID: 27676291
[TBL] [Abstract][Full Text] [Related]
4. Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial.
Cella D; Pickard AS; Duh MS; Guerin A; Mishagina N; Antràs L; Neary MP; McCann L; Hodge R; Sternberg CN
Eur J Cancer; 2012 Feb; 48(3):311-23. PubMed ID: 21689927
[TBL] [Abstract][Full Text] [Related]
5. Reference values of EORTC QLQ-C30, EORTC QLQ-BR23, and EQ-5D-5L for women with non-metastatic breast cancer at diagnosis and 2 years after.
Miret C; Orive M; Sala M; García-Gutiérrez S; Sarasqueta C; Legarreta MJ; Redondo M; Rivero A; Castells X; Quintana JM; Garin O; Ferrer M;
Qual Life Res; 2023 Apr; 32(4):989-1003. PubMed ID: 36630024
[TBL] [Abstract][Full Text] [Related]
6. Assessing the validity of EQ-5D-5L in people with head & neck cancer: Does a generic quality of life measure perform as well as a disease-specific measure in a patient population?
Davies A; Waylen A; Leary S; Thomas S; Pring M; Janssen B; Beynon R; Lang S; Schimansky S; Hurley K; Ness A
Oral Oncol; 2020 Feb; 101():104504. PubMed ID: 31835074
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life assessment for patients with advanced or metastatic renal cell carcinoma treated with a tyrosine kinase inhibitor using electronic patient-reported outcomes in daily clinical practice (QUANARIE trial): study protocol.
Mouillet G; Fritzsch J; Paget-Bailly S; Pozet A; Es-Saad I; Meurisse A; Vernerey D; Mouyabi K; Berthod D; Bonnetain F; Anota A; Thiery-Vuillemin A
Health Qual Life Outcomes; 2019 Feb; 17(1):25. PubMed ID: 30717745
[TBL] [Abstract][Full Text] [Related]
8. Converting EORTC QLQ-C30 scores to utility scores in the brigatinib ALTA study.
Kawata AK; Lenderking WR; Eseyin OR; Kerstein D; Huang J; Huang H; Zhang P; Lin HM
J Med Econ; 2019 Sep; 22(9):924-935. PubMed ID: 31125274
[No Abstract] [Full Text] [Related]
9. Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine practice.
Laquente B; Macarulla T; Bugés C; Martín M; García C; Pericay C; Merino S; Visa L; Martín T; Pedraza M; Carnero B; Guardeño R; Verdaguer H; Mut A; Vilanova D; García A
BMC Palliat Care; 2020 Jul; 19(1):103. PubMed ID: 32650765
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life, personality and choice of coping are related in renal cell carcinoma patients.
Beisland E; Beisland C; Hjelle KM; Bakke A; Aarstad AK; Aarstad HJ
Scand J Urol; 2015; 49(4):282-9. PubMed ID: 25515950
[TBL] [Abstract][Full Text] [Related]
11. Quality of life and supportive care for patients with metastatic renal cell carcinoma.
Lambea J; Hinojo C; Lainez N; Lázaro M; León L; Rodríguez A; Soto de Prado D; Esteban E
Cancer Metastasis Rev; 2012 Sep; 31 Suppl 1():S33-9. PubMed ID: 22684341
[TBL] [Abstract][Full Text] [Related]
12. Which Questionnaire Should Be Used to Measure Quality-of-Life Utilities in Patients with Acute Leukemia? An Evaluation of the Validity and Interpretability of the EQ-5D-5L and Preference-Based Questionnaires Derived from the EORTC QLQ-C30.
van Dongen-Leunis A; Redekop WK; Uyl-de Groot CA
Value Health; 2016; 19(6):834-843. PubMed ID: 27712712
[TBL] [Abstract][Full Text] [Related]
13. Measuring the Time to Deterioration for Health-Related Quality of Life in Patients With Metastatic Breast Cancer Using a Web-Based Monitoring Application: Longitudinal Cohort Study.
Brusniak K; Feisst M; Sebesteny L; Hartkopf A; Graf J; Engler T; Schneeweiss A; Wallwiener M; Deutsch TM
JMIR Cancer; 2021 Oct; 7(4):e25776. PubMed ID: 34636732
[TBL] [Abstract][Full Text] [Related]
14. Development of a disease-specific health-related quality of life (HRQoL) questionnaire intended to be used in conjunction with the general European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) in renal cell carcinoma patients.
Beisland E; Aarstad HJ; Aarstad AK; Bakke A; Bostad L; Beisland C
Acta Oncol; 2016; 55(3):349-56. PubMed ID: 26251300
[TBL] [Abstract][Full Text] [Related]
15. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.
Kontodimopoulos N; Aletras VH; Paliouras D; Niakas D
Value Health; 2009; 12(8):1151-7. PubMed ID: 19558372
[TBL] [Abstract][Full Text] [Related]
16. Sunitinib First-line Treatment in Metastatic Renal Cell Carcinoma: Costs and Effects.
Vuorinen RL; Paunu N; Turpeenniemi-Hujanen T; Reunamo T; Jekunen A; Kataja V; Sintonen H; Purmonen T; Kellokumpu-Lehtinen PL
Anticancer Res; 2019 Oct; 39(10):5559-5564. PubMed ID: 31570450
[TBL] [Abstract][Full Text] [Related]
17. Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry.
Müller V; Nabieva N; Häberle L; Taran FA; Hartkopf AD; Volz B; Overkamp F; Brandl AL; Kolberg HC; Hadji P; Tesch H; Ettl J; Lux MP; Lüftner D; Belleville E; Fasching PA; Janni W; Beckmann MW; Wimberger P; Hielscher C; Fehm TN; Brucker SY; Wallwiener D; Schneeweiss A; Wallwiener M
Breast; 2018 Feb; 37():154-160. PubMed ID: 29237546
[TBL] [Abstract][Full Text] [Related]
18. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life among prostate cancer patients: real-life situation at the beginning of treatment.
Bergius S; Torvinen S; Muhonen T; Roine RP; Sintonen H; Taari K
Scand J Urol; 2017 Feb; 51(1):13-19. PubMed ID: 27809631
[TBL] [Abstract][Full Text] [Related]
20. Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma - clinical application of health-related quality-of-life data.
Li L; Mo FK; Chan SL; Hui EP; Tang NS; Koh J; Leung LK; Poon AN; Hui J; Chu CM; Lee KF; Ma BB; Lai PB; Chan AT; Yu SC; Yeo W
BMC Cancer; 2017 Jan; 17(1):8. PubMed ID: 28052758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
